Pelthos Therapeutics Inc (PTHS)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$24.35-0.04%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PTHS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -62.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PTHS — legal / regulatory event
Dated 2026-08-13
of this Current Report on Form 8-K with CBIZ CPAs P.C., the Company's predecessor independent registered accounting firm, as well as with Grant Thornton LLP, the Company's current independent registered public accounting firm appointed on May 16, 2026, subsequent to the filing of the Form 10-Q for the Affected Period. Controls and Procedures In connection with this restatement, the Company has concluded that the misapplication of ASC 820 resulted from a material weakness in its internal contr…
Why it matters: If revenue growth in the healthcare sector picks up, it could benefit Pelthos.
Supportive ifHealthcare sector revenue growth is speeding up again. It is moving back toward highs above 10%.
Worry ifRevenue growth keeps slowing down. This shows weakness in the sector.
Why it matters: Earnings results will show the company's financial health and growth.
Watch forThe earnings report shows ZELSUVMI's revenue grew over $10.7 million.
Also watch forThe earnings report shows revenue below $10.7 million. This may signal problems.
Why it matters: Legal issues can affect how a company runs and its money. Progress or setbacks will change how investors feel.
Worry ifManagement says they resolved a major legal case.
Less concerning ifNew legal problems come up or current cases get worse.
Why it matters: Reaching this milestone shows strong demand and adoption for Zelsuvmi, the lead product.
Supportive ifUnits dispensed for Zelsuvmi exceed 30,000 since launch by the end of August 2026.
Worry ifUnits dispensed stay below 30,000 by the end of August 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$223 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $810 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,139 loss on $10,000 · 51.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash balance will show if the company is financially stable.
Supportive ifThe cash balance is over $32 million. This helps support ongoing operations.
Worry ifThe cash balance is below $32 million. This raises worries about liquidity.
Why it matters: Successful launches could bring in more money and lessen dependence on Zelsuvmi.
Watch forManagement confirms Xepi is on track for Q1 2027 launch.
Also watch forManagement delays the launch of Xepi beyond Q1 2027.
Why it matters: Legal cases can lead to fines or problems in operations. Outcomes are important.
Worry ifCourt rulings favor Pelthos, leading to reduced legal costs.
Less concerning ifCourt rulings against Pelthos could result in big fines.
Why it matters: Legal problems can affect how a company runs. They can also change how investors feel.
Worry ifA major legal issue is resolved.
Less concerning ifNew legal problems come up or old ones get worse.
Why it matters: Lower growth means Zelsuvmi may not be accepted in the market as well. It could hurt sales.
Worry ifZelsuvmi revenue growth in Q3 is less than 30% compared to Q2.
Less concerning ifZelsuvmi revenue growth in Q3 exceeds 30% compared to Q2.
Why it matters: A lower cash balance may hurt Pelthos's ability to fund its operations and growth.
Worry ifCash balance reported below $20 million in the next quarterly update.
Less concerning ifCash balance stays above $20 million. This shows better liquidity.